Dr. Bhargava is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 N Wolfe St
# Patholog
Baltimore, MD 21287Phone+1 410-614-1522Fax+1 410-502-6736
Summary
- Dr. Pavan Bhargava is a neurologist in Baltimore, MD and is affiliated with Johns Hopkins Hospital. He received his medical degree from Christian Medical College Vellore and has been in practice 12 years. He specializes in neuroimmunology/multiple sclerosis and neurophysiology and is experienced in multiple sclerosis.
Education & Training
Johns Hopkins UniversityFellowship, Neuroimmunology & Multiple Sclerosis, 2013 - 2016
Southern Illinois UniversityResidency, Neurology, 2009 - 2013- Southern Illinois UniversityResidency, Internal Medicine, 2009 - 2010
Christian Medical College VelloreClass of 2005
Certifications & Licensure
MD State Medical License 2015 - 2026
IL State Medical License 2012 - 2017- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Start of enrollment: 2014 Nov 01
- A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis Start of enrollment: 2018 Jun 19
- Ocrelizumab Effects on the Metabolome in MS Start of enrollment: 2019 Jun 12
Publications & Presentations
PubMed
- Spatial transcriptomics of meningeal inflammation reveals inflammatory gene signatures in adjacent brain parenchyma.Sachin P Gadani, Saumitra Singh, Sophia Kim, Jingwen Hu, Matthew D Smith
Elife. 2024-10-30 - Restoring the Multiple Sclerosis Associated Imbalance of Gut Indole Metabolites Promotes Remyelination and Suppresses Neuroinflammation.Larissa Jank, Saumitra S Singh, Judy Lee, Asmita Dhukhwa, Fatemeh Siavoshi
Biorxiv. 2024-10-28 - Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease.Dimitrios C Ladakis, Kimystian L Harrison, Matthew D Smith, Krista Solem, Sachin Gadani
Med. 2024-10-23
Press Mentions
National MS Society Invests $8.7M in Research, Clinical Trial TrainingSeptember 9th, 2021- AI Tool Reveals MS Drug Interactions, Offers Safer OptionsOctober 14th, 2023
- Smoldering Inflammation in MS: Insights and Emerging TherapiesAugust 8th, 2024
Professional Memberships
- Fellow
External Links
- Lab websitehttp://bhargavalaboratory.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
